Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Angelos Stergiou |
Contact Details
Address: 7 Times Square, Suite 2503 New York, New York 10036 United States | |
| Phone | 646 200 5278 |
| Website | sellaslifesciences.com |
Stock Details
| Ticker Symbol | SLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001390478 |
| CUSIP Number | 81642T209 |
| ISIN Number | US81642T2096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer and Director |
| John Thomas Burns CPA | Senior Vice President and Chief Financial Officer |
| Stacy E. Yeung | Vice President of Legal Affairs, Head of Compliance and Corporate Secretary |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development |
| Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Jan 29, 2025 | 424B5 | Filing |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |